Other Information
−Removed: January 2018, John Erick and Deborah Ferrell, successors-in-interest and heirs of Jade Erick, (collectively “Erick”) filed
−Removed: a lawsuit in the San Diego County Superior Court against Kim Kelly, ND, MPH asserting claims related to the death of Jade Erick.
−Removed: 2018, Erick filed an amendment to the lawsuit, naming us as a co-defendant.
−Removed: In September 2018, co-defendant Dr.
−Removed: Kelly filed a cross-complaint
−Removed: against the Company and various entities affiliated with Spectrum Laboratory Products, Inc., Spectrum Chemical Manufacturing Corp.
−Removed: Spectrum Pharmacy Products, Inc.
−Removed: (collectively “Spectrum”).
−Removed: The cross-complaint sought indemnity and contribution from us
−Removed: and Spectrum.
−Removed: In November 2021, the lawsuit involving us was resolved.
−Removed: There was no impact to our consolidated financial position and
−Removed: results of operations as a result of the resolution of the case.
−Removed: License and Supply Agreement, dated as of July 25, 2021, by and between the Company and Sintetica, S.A.
−Removed: (incorporated herein by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of the Company filed with the SEC on August 10, 2021).
−Removed: Loan and Security Agreement, dated September 1, 2021, by and between the Company and Melt Pharmaceuticals, Inc.
−Removed: (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed with the SEC on September 2, 2021).
−Removed: Basic Sale and Purchase Agreement, dated as of August 18, 2021, by and between the Company and Wakamoto Pharmaceutical Co., Ltd.
−Removed: License Agreement, dated as of August 18, 2021, by and between the Company and Wakamoto Pharmaceutical Co., Ltd.
Certification of Mark L.
13 unchanged sentences
XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, has been formatted in
+Added: cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, has been formatted in Inline
of this exhibit have been omitted in compliance with Item 601 of Regulation S-K.
1 unchanged sentence
the undersigned, thereunto duly authorized.
−Removed: November 9, 2021
Executive Officer and Director
Executive Officer)
−Removed: Financial Officer (Principal Financial and Accounting Officer)
+Added: Chief Financial Officer
+Added: (Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.